# reload+after+2024-01-23 17:46:26.862413
address1§12 Penns Trail
city§Newtown
state§PA
zip§18940
country§United States
phone§267 759 3680
fax§267 759 3681
website§https://www.onconova.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
fullTimeEmployees§16
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Steven M. Fruchtman M.D.', 'age': 72, 'title': 'CEO, President & Director', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 907859, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mark Patrick Guerin CPA', 'age': 54, 'title': 'CFO & COO', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 629267, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Victor  Moyo M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.489
priceToSalesTrailing12Months§68.902306
currency§USD
dateShortInterest§1702598400
forwardEps§-0.88
exchange§NCM
quoteType§EQUITY
shortName§Onconova Therapeutics, Inc.
longName§Onconova Therapeutics, Inc.
firstTradeDateEpochUtc§1374759000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§1378b955-1a00-3a94-8f5b-f7e1a2a87131
gmtOffSetMilliseconds§-18000000
targetHighPrice§11.0
targetLowPrice§7.0
targetMeanPrice§8.33
targetMedianPrice§7.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§2.611
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
